Stock GILD GILEAD SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up
PDF Report : Gilead Sciences, Inc.

Company Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2023-12-05 pm EST 		Intraday chart for Gilead Sciences, Inc. 5-day change 1st Jan Change
79.02 USD +0.87% +6.05% -7.96%
Dec. 04 IDEAYA Biosciences Collaborates With Gilead Sciences to Evaluate Combination of Trodelvy, IDE397 for Bladder Cancer MT
Dec. 04 Ideaya Biosciences, Inc. Announces Clinical Study Collaboration with Gilead Sciences, Inc. to Evaluate Trodelvy and Ide397 Combination in Mtap-Deletion Bladder Cancer CI

Business Summary

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:

- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);

- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.

Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Number of employees : 17,000

Sales per Business

USD in Million2021Weight2022Weight Delta
Innovative Medicines
100.0 %
27,305 100.0 % 27,281 100.0 % -0.09%

Sales per region

USD in Million2021Weight2022Weight Delta
United States
69.2 %
19,267 70.6 % 18,884 69.2 % -1.99%
Europe
16.4 %
4,874 17.9 % 4,469 16.4 % -8.31%
Other International
14.4 %
3,164 11.6 % 3,928 14.4 % +24.15%

Managers

Managers TitleAgeSince
Daniel O'Day CEO
 Chief Executive Officer 58 2019
Andrew Dickinson DFI
 Director of Finance/CFO 53 2015
Flavius Martin CTO
 Chief Tech/Sci/R&D Officer - 2021
Merdad Parsey CTO
 Chief Tech/Sci/R&D Officer 60 2019
Jacquie Ross IRC
 Investor Relations Contact - 2020
Janet Dorling PRN
 Corporate Officer/Principal 49 2020
Adam Levy PRN
 Corporate Officer/Principal - -
Stacey Ma PRN
 Corporate Officer/Principal 53 2022
Mark Genovese PRN
 Corporate Officer/Principal - 2020
Tomas Cihlar PRN
 Corporate Officer/Principal - -

Members of the board

Members of the board TitleAgeSince
Anthony Welters BRD
 Director/Board Member 68 2020
Jacqueline K. Barton BRD
 Director/Board Member 70 2017
Kevin Lofton BRD
 Director/Board Member 68 2009
Harish M. Manwani BRD
 Director/Board Member 69 2018
Javier Rodriguez BRD
 Director/Board Member 52 2020
Daniel O'Day CEO
 Chief Executive Officer 58 2019
Sandra Horning BRD
 Director/Board Member 74 2020
Kelly Kramer BRD
 Director/Board Member 55 2016
Jeffrey A. Bluestone BRD
 Director/Board Member 69 2020

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,246,041,895 1,244,607,836 ( 99.88 %) 0 99.88 %

Shareholders

NameEquities%Valuation
The Vanguard Group, Inc.
8.629 %
107,519,953 8.629 % 8 445 M $
Capital Research & Management Co. (World Investors)
6.824 %
85,024,189 6.824 % 6 678 M $
Capital Research & Management Co. (Global Investors)
3.318 %
41,348,459 3.318 % 3 248 M $
Dodge & Cox
2.200 %
27,411,892 2.200 % 2 153 M $
Geode Capital Management LLC
1.807 %
22,511,915 1.807 % 1 768 M $
Fidelity Management & Research Co. LLC
1.385 %
17,256,433 1.385 % 1 355 M $
Wellington Management Co. LLP
1.128 %
14,061,052 1.128 % 1 104 M $
Norges Bank Investment Management
1.043 %
12,989,938 1.043 % 1 020 M $
Capital International Ltd.
0.8633 %
10,756,580 0.8633 % 845 M $
Parnassus Investments LLC
0.8619 %
10,739,410 0.8619 % 843 M $
NameEquities%Valuation
Bram Bradesco Asset Management S/A DTVM
0.000294 %
7,330 0.000294 % 285 002 $
BB Gestão de Recursos DTVM SA
0.000284 %
7,086 0.000284 % 275 515 $
Western Asset Management Company DTVM Ltda.
0.000101 %
2,516 0.000101 % 97 826 $

Holdings

NameEquities%Valuation
GALAPAGOS NV
25.35%
 16,707,477 25.35% 551,515,654 $
ASSEMBLY BIOSCIENCES, INC.
24.84%
 13,073,668 24.84% 11,465,607 $
ARCUS BIOSCIENCES, INC.
19.90%
 14,823,029 19.90% 232,869,786 $
ALLOVIR, INC.
14.61%
 16,635,286 14.61% 24,952,929 $
ARCELLX, INC.
7.19%
 3,478,261 7.19% 122,608,700 $
IKENA ONCOLOGY, INC.
6.69%
 2,931,467 6.69% 11,813,812 $
TANGO THERAPEUTICS, INC.
4.77%
 4,854,443 4.77% 40,777,321 $
HOOKIPA PHARMA INC.
4.61%
 3,759,465 4.61% 1,624,089 $

Company contact information

Gilead Sciences, Inc.

333 Lakeside Drive

94404, Foster City

+650 574 3000

http://www.gilead.com
address Gilead Sciences, Inc.(GILD)

Group companies

NameCategory and Sector
Gilead Sciences Ireland UC
-
Gilead Therapeutics A1 Unlimited Co.
Health Technology - Pharmaceuticals: Major

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sales per region

Ratings for Gilead Sciences, Inc.

Trading Rating :
Investor Rating :
ESG Refinitiv :
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
79.02USD
Average target price
90.39USD
Spread / Average Target
+14.39%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
GILEAD SCIENCES, INC. Stock Gilead Sciences, Inc.
-7.96% 97 615 M $
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+60.77% 527 B $
NOVO NORDISK A/S Stock Novo Nordisk A/S
+46.50% 448 B $
JOHNSON & JOHNSON Stock Johnson & Johnson
-10.25% 382 B $
MERCK & CO., INC. Stock Merck & Co., Inc.
-4.25% 266 B $
ABBVIE INC. Stock AbbVie Inc.
-10.54% 255 B $
ROCHE HOLDING AG Stock Roche Holding AG
-13.61% 227 B $
NOVARTIS AG Stock Novartis AG
+1.76% 203 B $
ASTRAZENECA PLC Stock AstraZeneca PLC
-9.57% 201 B $
PFIZER, INC. Stock Pfizer, Inc.
-43.23% 165 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock Gilead Sciences, Inc. - Nasdaq
  4. Company Gilead Sciences, Inc.
Secure and Increase the Performance of your Investments with our Team of Experts at your Side
Securing my Investments
fermer